After flirting with minor gains and losses by Sarepta Therapeutics Inc (NASDAQ:SRPT) duchenne muscular dystrophy drug eteplirsen, the firm seems to be back from the dead with the FDA explaining paths to a new drug application by the end of the year. Sarepta Therapeutics Inc (NASDAQ:SRPT) shares after opening at $37.37 moved to $38.13 on last trade day and at the end of the day closed at $36.70. Company price to sales ratio in past twelve months was calculated as 97.62 and price to cash ratio as 5.39. Sarepta Therapeutics Inc (NASDAQ:SRPT) showed a positive weekly performance of 50.41%.
GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH) continues to surge in the market by highs of 12.17% at the back of the company’s stock receiving major endorsements. Morgan Stanley kick started the endorsements by starting coverage with an “Overweight” rating. They currently have a $103 share price target on the company’s stock which is an 80% compared to the current trading margins. The second endorsement that is uplifting GW Pharmaceuticals in the markets comes from Jim Cramer. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares fell -8.51% in last trading session and ended the day on $62.12. GWPH return on equity ratio is recorded as -33.10% and its return on assets is -18.10%.
Prothena Corp (NASDAQ:PRTA) was upgraded by stock analysts at Wedbush to a “best ideas list” rating in a report issued on Friday. Prothena Corporation PLC (NASDAQ:PRTA) shares moved down -2.62% in last trading session and was closed at $38.58, while trading in range of $37.98-$39.92. Prothena Corporation PLC (NASDAQ:PRTA) year to date performance is 45.48%.
Revance Therapeutics Inc (NASDAQ:RVNC) announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance’s proprietary, injectable botulinum toxin investigational product that incorporates the patented TransMTS® technology and is designed to provide a longer lasting duration of effect. In the study, RT002 met its primary efficacy and safety endpoints. Revance Therapeutics Inc (NASDAQ:RVNC) weekly performance is 21.39%. On last trading day company shares ended up $34.33. Revance Therapeutics Inc (NASDAQ:RVNC) distance from 50-day simple moving average is 9.92%. Analysts mean target price for the company is $45.33.